Free Trial
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free DSGN Stock Alerts

Design Therapeutics (DSGN) Financials

Design Therapeutics logo
$10.91 -0.74 (-6.35%)
Closing price 10/12/2026 04:00 PM Eastern
Extended Trading
$10.85 -0.06 (-0.55%)
As of 08:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Design Therapeutics

Annual Income Statements for Design Therapeutics

This table shows Design Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -8.28 -36 -63 -67 -50 -70
Consolidated Net Income / (Loss)		 -8.28 -36 -63 -67 -50 -70
Net Income / (Loss) Continuing Operations		 -8.28 -36 -63 -67 -50 -70
Total Pre-Tax Income 		-8.28 -36 -63 -67 -50 -70
Total Operating Income		 -8.33 -36 -68 -78 -62 -79
Total Gross Profit		 0.23 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.23 0.00 0.00 0.00 0.00 0.00
Operating Revenue		 0.23 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 8.56 36 68 78 62 79
Selling, General & Admin Expense		 2.50 11 19 21 18 20
Research & Development Expense		 6.06 25 49 57 44 59
Total Other Income / (Expense), net		 0.05 0.30 4.29 11 13 9.68
Interest & Investment Income		 - - - 11 13 9.68
Basic Earnings per Share		 ($0.52) ($0.77) ($1.14) ($1.19) ($0.88) ($1.22)
Weighted Average Basic Shares Outstanding		 15.80M 45.94M 55.71M 55.98M 56.59M 57.33M
Diluted Earnings per Share		 ($0.52) ($0.77) ($1.14) ($1.19) ($0.88) ($1.22)
Weighted Average Diluted Shares Outstanding		 15.80M 45.94M 55.71M 55.98M 56.59M 57.33M
Weighted Average Basic & Diluted Shares Outstanding		 15.80M 45.94M 55.94M 56.49M 56.76M 61.67M

Quarterly Income Statements for Design Therapeutics

This table shows Design Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -12 -11 -12 -13 -14 -18 -19 -17 -16 -18 -20
Consolidated Net Income / (Loss)		 -12 -11 -12 -13 -14 -18 -19 -17 -16 -18 -20
Net Income / (Loss) Continuing Operations		 -12 -11 -12 -13 -14 -18 -19 -17 -16 -18 -20
Total Pre-Tax Income 		-12 -11 -12 -13 -14 -18 -19 -17 -16 -18 -20
Total Operating Income		 -15 -14 -15 -16 -17 -20 -22 -19 -18 -20 -22
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 15 14 15 16 17 20 22 19 18 20 22
Selling, General & Admin Expense		 4.11 4.60 4.53 4.37 4.54 5.04 5.83 4.72 4.74 5.33 5.79
Research & Development Expense		 11 9.80 11 12 12 15 16 15 13 14 16
Total Other Income / (Expense), net		 3.28 3.30 3.25 3.21 3.04 2.70 2.49 2.31 2.17 2.07 2.01
Interest & Investment Income		 - 3.30 3.25 3.21 - 2.70 2.49 2.31 2.17 2.07 2.01
Other Income / (Expense), net		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Basic Earnings per Share		 ($0.20) ($0.20) ($0.21) ($0.23) ($0.24) ($0.31) ($0.34) ($0.30) ($0.27) ($0.29) ($0.32)
Weighted Average Basic Shares Outstanding		 55.98M 56.49M 56.56M 56.62M 56.59M 56.76M 56.86M 56.95M 57.33M 61.43M 62.51M
Diluted Earnings per Share		 ($0.20) ($0.20) ($0.21) ($0.23) ($0.24) ($0.31) ($0.34) ($0.30) ($0.27) ($0.29) ($0.32)
Weighted Average Diluted Shares Outstanding		 55.98M 56.49M 56.56M 56.62M 56.59M 56.76M 56.86M 56.95M 57.33M 61.43M 62.51M
Weighted Average Basic & Diluted Shares Outstanding		 56.49M 56.50M 56.62M 56.62M 56.76M 56.77M 56.95M 56.96M 61.67M 62.46M 62.58M

Annual Cash Flow Statements for Design Therapeutics

This table details how cash moves in and out of Design Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 2.30 296 -272 -5.30 1.36 -5.71
Net Cash From Operating Activities		 -8.67 -29 -51 -59 -43 -54
Net Cash From Continuing Operating Activities		 -8.67 -29 -51 -59 -43 -54
Net Income / (Loss) Continuing Operations		 -8.28 -36 -63 -67 -50 -70
Consolidated Net Income / (Loss)		 -8.28 -36 -63 -67 -50 -70
Depreciation Expense		 0.01 0.13 0.41 0.54 0.60 0.62
Amortization Expense		 -0.07 -0.08 -1.40 -6.08 -6.20 -3.25
Non-Cash Adjustments To Reconcile Net Income		 0.49 4.71 11 13 13 15
Changes in Operating Assets and Liabilities, net		 -0.81 1.40 2.00 0.73 -0.99 3.11
Net Cash From Investing Activities		 -34 -54 -221 53 44 23
Net Cash From Continuing Investing Activities		 -34 -54 -221 53 44 23
Purchase of Property, Plant & Equipment		 -0.08 -1.54 -0.92 -0.26 -0.34 -0.19
Purchase of Investments		 -56 -86 -313 -225 -230 -292
Sale of Property, Plant & Equipment		 - 0.00 0.04 0.00 0.00 0.00
Sale and/or Maturity of Investments		 22 34 93 277 274 315
Net Cash From Financing Activities		 45 379 0.24 0.72 0.51 26
Net Cash From Continuing Financing Activities		 45 379 0.24 0.72 0.51 26
Repayment of Debt		 -0.40 0.00 -0.43 0.00 0.00 0.00
Issuance of Common Equity		 0.00 254 0.34 0.31 0.48 25
Other Financing Activities, net		 0.00 0.03 0.32 0.42 0.04 0.24

Quarterly Cash Flow Statements for Design Therapeutics

This table details how cash moves in and out of Design Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -6.74 8.20 16 -15 -7.77 -8.90 6.04 -4.62 1.77 -4.09 0.14
Net Cash From Operating Activities		 -13 -12 -11 -9.55 -9.86 -17 -14 -11 -12 -16 -16
Net Cash From Continuing Operating Activities		 -13 -12 -11 -9.55 -9.86 -17 -14 -11 -12 -16 -16
Net Income / (Loss) Continuing Operations		 -12 -11 -12 -13 -14 -18 -19 -17 -16 -18 -20
Consolidated Net Income / (Loss)		 -12 -11 -12 -13 -14 -18 -19 -17 -16 -18 -20
Depreciation Expense		 0.14 0.14 0.15 0.15 0.15 0.16 0.15 0.16 0.16 0.16 0.15
Amortization Expense		 -1.84 -1.73 -1.57 -1.46 -1.44 -1.06 -0.91 -0.77 -0.51 -0.15 -0.02
Non-Cash Adjustments To Reconcile Net Income		 2.73 3.19 3.30 3.12 3.47 3.54 4.41 3.58 3.43 3.99 3.94
Changes in Operating Assets and Liabilities, net		 -1.99 -2.93 -1.35 1.68 1.61 -1.71 0.99 2.86 0.96 -2.80 0.56
Net Cash From Investing Activities		 5.56 21 27 -5.83 1.83 7.87 20 6.51 -12 -7.59 15
Net Cash From Continuing Investing Activities		 5.56 21 27 -5.83 1.83 7.87 20 6.51 -12 -7.59 15
Purchase of Property, Plant & Equipment		 -0.03 -0.20 -0.16 0.02 - -0.07 -0.09 - -0.03 0.00 -0.02
Purchase of Investments		 -74 -46 -54 -67 -64 -87 -40 -78 -88 -53 -12
Sale and/or Maturity of Investments		 80 66 81 61 66 94 60 85 76 45 28
Net Cash From Financing Activities		 0.50 0.02 0.23 0.00 0.26 0.02 0.36 0.04 25 20 0.61
Net Cash From Continuing Financing Activities		 0.50 0.02 0.23 0.00 0.26 0.02 0.36 0.04 25 20 0.61
Issuance of Common Equity		 0.10 - - - 0.25 0.00 - - 25 20 0.46
Other Financing Activities, net		 0.40 0.02 0.01 0.00 0.01 0.02 - 0.04 0.18 0.03 0.14

Annual Balance Sheets for Design Therapeutics

This table presents Design Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 37 391 341 290 252 226
Total Current Assets		 36 385 335 285 248 224
Cash & Equivalents		 2.38 299 27 21 23 17
Short-Term Investments		 34 85 304 261 223 203
Prepaid Expenses		 0.14 1.37 4.73 2.79 2.56 3.94
Plant, Property, & Equipment, net		 0.07 1.51 1.95 1.69 1.41 0.98
Total Noncurrent Assets		 0.21 3.61 4.07 3.37 2.64 1.44
Other Noncurrent Operating Assets		 0.21 3.61 4.07 3.37 2.64 1.44
Total Liabilities & Shareholders' Equity		 37 391 341 290 252 226
Total Liabilities		 2.48 8.43 14 12 10.00 14
Total Current Liabilities		 2.33 5.28 11 9.62 8.46 13
Accounts Payable		 2.33 5.28 11 9.62 8.46 13
Total Noncurrent Liabilities		 0.15 3.14 3.05 2.33 1.53 0.65
Other Noncurrent Operating Liabilities		 0.15 3.14 3.05 2.33 1.53 0.65
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -11 382 327 278 242 213
Total Preferred & Common Equity		 -11 382 327 278 242 213
Total Common Equity		 -11 382 327 278 242 213
Common Stock		 0.45 430 441 455 469 509
Retained Earnings		 -12 -47 -111 -178 -227 -297
Accumulated Other Comprehensive Income / (Loss)		 0.16 -0.24 -3.36 0.06 0.48 0.40

Quarterly Balance Sheets for Design Therapeutics

This table presents Design Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 300 279 270 262 237 223 212 230 215
Total Current Assets		 295 274 265 257 234 220 209 227 212
Cash & Equivalents		 28 29 46 30 14 20 15 13 13
Short-Term Investments		 263 241 215 224 216 197 191 210 194
Prepaid Expenses		 3.60 3.20 3.83 3.17 3.97 3.52 3.06 4.23 4.62
Plant, Property, & Equipment, net		 1.78 1.72 1.73 1.56 1.38 1.26 1.10 0.82 0.69
Total Noncurrent Assets		 3.55 3.19 3.01 2.83 2.45 1.83 1.64 2.57 2.42
Other Noncurrent Operating Assets		 3.55 3.19 3.01 2.83 2.45 1.83 1.64 2.57 2.42
Total Liabilities & Shareholders' Equity		 300 279 270 262 237 223 212 230 215
Total Liabilities		 15 9.24 8.34 9.18 9.56 9.85 12 12 13
Total Current Liabilities		 12 7.09 6.39 7.43 8.24 8.75 11 10 11
Accounts Payable		 12 7.09 6.39 7.43 8.24 8.75 11 10 11
Total Noncurrent Liabilities		 2.52 2.14 1.95 1.74 1.32 1.10 0.88 2.20 2.03
Other Noncurrent Operating Liabilities		 2.52 2.14 1.95 1.74 1.32 1.10 0.88 2.20 2.03
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 285 270 261 252 228 213 200 218 202
Total Preferred & Common Equity		 285 270 261 252 228 213 200 218 202
Total Common Equity		 285 270 261 252 228 213 200 218 202
Common Stock		 452 458 462 465 472 477 480 533 537
Retained Earnings		 -166 -189 -201 -214 -245 -264 -281 -315 -335
Accumulated Other Comprehensive Income / (Loss)		 -1.28 -0.17 -0.22 0.91 0.45 0.31 0.36 -0.27 -0.77

Annual Metrics And Ratios for Design Therapeutics

This table displays calculated financial ratios and metrics derived from Design Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 55,662,501.00 55,910,071.00 56,001,992.00 - 56,963,757.00
DEI Adjusted Shares Outstanding		 0.00 55,662,501.00 55,910,071.00 56,001,992.00 - 56,963,757.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -0.64 -1.13 -1.19 - -1.23
Growth Metrics		 - - - - - -
Profitability Metrics		 - - - - - -
Net Operating Profit after Tax (NOPAT)		 -5.83 -25 -47 -55 -44 -56
Return On Investment Capital (ROIC_SIMPLE)		 - - - -19.71% -18.04% -26.18%
Earnings before Interest and Taxes (EBIT)		 -8.28 -36 -63 -78 -62 -79
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -8.35 -35 -64 -84 -68 -82
Valuation Ratios		 - - - - - -
Leverage & Solvency		 - - - - - -
Liquidity Ratios		 - - - - - -
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -25 -46 -54 -44 -52
Efficiency Ratios		 - - - - - -
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -2.05 -1.93 -3.08 -4.11 -3.38 -7.34
Increase / (Decrease) in Invested Capital		 0.00 0.12 -1.14 -1.03 0.73 -3.96
Book Value per Share		 ($0.72) $6.87 $5.85 $4.96 $4.28 $3.73
Tangible Book Value per Share		 ($0.72) $6.87 $5.85 $4.96 $4.28 $3.73
Total Capital		 34 382 327 278 242 213
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -36 -384 -330 -282 -245 -220
Capital Expenditures (CapEx)		 0.08 1.54 0.88 0.26 0.34 0.19
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.19 -3.91 -6.04 -6.84 -5.90 -9.12
Debt-free Net Working Capital (DFNWC)		 34 380 324 275 240 211
Net Working Capital (NWC)		 34 380 324 275 240 211
Net Nonoperating Expense (NNE)		 2.45 10 16 12 5.92 14
Net Nonoperating Obligations (NNO)		 -36 -384 -330 -282 -245 -220
Total Depreciation and Amortization (D&A)		 -0.07 0.05 -0.99 -5.55 -5.60 -2.63
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.77) ($1.14) ($1.19) ($0.88) ($1.22)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 55.70M 55.71M 55.98M 56.59M 57.33M
Adjusted Diluted Earnings per Share		 $0.00 ($0.77) ($1.14) ($1.19) ($0.88) ($1.22)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 55.70M 55.71M 55.98M 56.59M 57.33M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.77) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 45.94M 55.94M 56.49M 56.76M 61.67M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.83 -25 -47 -55 -44 -56
Debt Service Ratios		 - - - - - -
Payout Ratios		 - - - - - -

Quarterly Metrics And Ratios for Design Therapeutics

This table displays calculated financial ratios and metrics derived from Design Therapeutics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 56,001,992.00 56,494,271.00 56,495,039.00 56,620,525.00 - 56,762,678.00 56,768,678.00 56,948,126.00 56,963,757.00 61,672,279.00 62,456,974.00
DEI Adjusted Shares Outstanding		 56,001,992.00 56,494,271.00 56,495,039.00 56,620,525.00 - 56,762,678.00 56,768,678.00 56,948,126.00 56,963,757.00 61,672,279.00 62,456,974.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.21 -0.20 -0.21 -0.23 - -0.31 -0.34 -0.30 -0.28 -0.29 -0.32
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBITDA Growth		 7.15% 21.27% 22.34% -1.08% -6.92% -33.34% -35.63% -13.53% - 7.61% 1.30%
EBIT Growth		 12.80% 25.37% 24.55% -2.89% -10.40% -41.79% -43.38% -18.87% - 3.49% -2.82%
NOPAT Growth		 22.02% 33.49% 33.43% 13.69% -10.40% -41.79% -43.38% -18.87% - 3.49% -2.82%
Net Income Growth		 31.71% 42.44% 40.85% 17.42% -15.28% -59.52% -61.82% -30.36% - 0.45% -5.67%
EPS Growth		 35.48% 42.86% 41.67% 17.86% -20.00% -55.00% -61.90% -30.43% - 6.45% 5.88%
Operating Cash Flow Growth		 15.19% 28.61% 18.43% 34.32% 22.96% -34.97% -28.25% -16.93% - 2.13% -7.50%
Free Cash Flow Firm Growth		 23.17% 14.58% 41.88% -43.65% -30.01% -18.58% -8.16% 43.51% - 21.12% -13.68%
Invested Capital Growth		 -33.60% 56.14% 0.00% 72.91% 17.78% -55.45% -1,533.19% -285.56% - -171.74% -70.98%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBITDA Q/Q Growth		 3.12% 4.94% -2.98% -6.58% -25.39% -18.55% -4.75% 10.78% - -6.32% -11.91%
EBIT Q/Q Growth		 4.23% 4.77% -4.47% -8.00% -28.03% -22.31% -5.64% 10.47% - -8.46% -12.54%
NOPAT Q/Q Growth		 19.66% 4.77% -4.47% -8.00% -2.76% -22.31% -5.64% 10.47% - -8.46% -12.54%
Net Income Q/Q Growth		 25.00% 6.22% -6.20% -10.57% -4.69% -29.77% -7.72% 10.93% - -10.25% -14.34%
EPS Q/Q Growth		 28.57% 0.00% -5.00% -9.52% -4.35% -29.17% -9.68% 11.76% - -7.41% -10.34%
Operating Cash Flow Q/Q Growth		 11.94% 2.81% 9.48% 15.22% -3.29% -70.27% 13.99% 22.71% - -37.31% 5.52%
Free Cash Flow Firm Q/Q Growth		 12.81% -20.67% 6.67% -46.28% 21.08% -10.07% 14.88% 23.59% - -23.11% -22.68%
Invested Capital Q/Q Growth		 31.29% 72.54% 120.02% -817.26% -108.51% 48.08% -84.56% -92.96% - 35.04% -16.13%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00%
Interest Burden Percent		 78.31% 77.12% 78.40% 80.26% 81.77% 86.76% 88.47% 88.02% - 89.50% 90.93%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Equity (ROE)		 -22.10% -20.15% -19.34% -17.78% -19.08% -22.59% -26.77% -29.83% - -31.26% -34.13%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -39,465.66% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Common Equity (ROCE)		 -22.10% -20.15% -19.34% -17.78% -19.08% -22.59% -26.77% -29.83% - -31.26% -34.13%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -21.77% 0.00% 0.00% 0.00% -24.66% 0.00% 0.00% - 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 -10 -11 -11 -12 -14 -15 -14 -13 -14 -16
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -0.41% -0.35% -0.97% -0.61% -0.75% -1.37% -1.67% -1.51% - -1.70% -2.19%
Return On Investment Capital (ROIC_SIMPLE)		 -3.81% -3.74% -4.03% -4.50% -4.83% -6.27% -7.09% -6.77% -5.99% -6.33% -7.69%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -15 -14 -15 -16 -17 -20 -22 -19 -18 -20 -22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -17 -16 -16 -18 -18 -21 -22 -20 -19 -20 -22
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.53 0.84 0.72 1.21 1.44 0.96 0.90 2.15 - 3.01 4.48
Price to Tangible Book Value (P/TBV)		 0.53 0.84 0.72 1.21 1.44 0.96 0.90 2.15 - 3.01 4.48
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Financial Leverage		 -1.01 -1.01 -1.00 -1.01 -1.01 -1.01 -1.01 -1.02 - -1.01 -1.02
Leverage Ratio		 1.04 1.04 1.03 1.04 1.04 1.04 1.04 1.05 - 1.05 1.06
Compound Leverage Factor		 0.82 0.80 0.81 0.84 0.85 0.90 0.92 0.92 - 0.94 0.96
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Altman Z-Score		 7.56 14.82 13.54 19.72 20.63 13.17 10.81 20.31 - 30.72 39.46
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 29.58 38.61 41.42 34.61 29.31 28.37 25.13 18.71 - 22.28 18.86
Quick Ratio		 29.29 38.16 40.82 34.19 29.01 27.89 24.73 18.43 - 21.87 18.45
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -9.55 -12 -11 -16 -12 -14 -12 -8.89 -8.76 -11 -13
Operating Cash Flow to CapEx		 -47,400.00% -6,378.97% -6,993.79% 0.00% 0.00% -23,318.06% -16,598.85% 0.00% - 0.00% -73,923.81%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -4.11 -1.13 0.23 -1.62 -3.38 -1.76 -3.24 -6.25 -7.34 -4.77 -5.54
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Increase / (Decrease) in Invested Capital		 -1.03 1.45 0.23 4.36 0.73 -0.63 -3.47 -4.63 -3.96 -3.01 -2.30
Enterprise Value (EV)		 -133 -43 -72 51 104 -11 -25 223 - 433 696
Market Capitalization		 148 228 189 305 349 219 191 429 - 656 904
Book Value per Share		 $4.96 $4.77 $4.62 $4.46 $4.28 $4.02 $3.75 $3.51 $3.73 $3.54 $3.23
Tangible Book Value per Share		 $4.96 $4.77 $4.62 $4.46 $4.28 $4.02 $3.75 $3.51 $3.73 $3.54 $3.23
Total Capital		 278 270 261 252 242 228 213 200 213 218 202
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -282 -271 -261 -254 -245 -230 -216 -206 -220 -223 -207
Capital Expenditures (CapEx)		 0.03 0.20 0.16 -0.02 0.00 0.07 0.09 0.00 0.03 0.00 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.84 -3.89 -2.57 -4.26 -5.90 -4.27 -5.23 -8.11 -9.12 -5.96 -6.62
Debt-free Net Working Capital (DFNWC)		 275 267 258 250 240 225 211 198 211 217 201
Net Working Capital (NWC)		 275 267 258 250 240 225 211 198 211 217 201
Net Nonoperating Expense (NNE)		 1.26 1.03 1.26 1.67 1.97 3.42 3.98 3.48 3.28 3.84 4.64
Net Nonoperating Obligations (NNO)		 -282 -271 -261 -254 -245 -230 -216 -206 -220 -223 -207
Total Depreciation and Amortization (D&A)		 -1.70 -1.59 -1.42 -1.30 -1.29 -0.90 -0.76 -0.61 -0.36 0.01 0.14
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.20) ($0.20) ($0.21) ($0.23) ($0.24) ($0.31) ($0.34) ($0.30) ($0.27) ($0.29) ($0.32)
Adjusted Weighted Average Basic Shares Outstanding		 55.98M 56.49M 56.56M 56.62M 56.59M 56.76M 56.86M 56.95M 57.33M 61.43M 62.51M
Adjusted Diluted Earnings per Share		 ($0.20) ($0.20) ($0.21) ($0.23) ($0.24) ($0.31) ($0.34) ($0.30) ($0.27) ($0.29) ($0.32)
Adjusted Weighted Average Diluted Shares Outstanding		 55.98M 56.49M 56.56M 56.62M 56.59M 56.76M 56.86M 56.95M 57.33M 61.43M 62.51M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 56.49M 56.50M 56.62M 56.62M 56.76M 56.77M 56.95M 56.96M 61.67M 62.46M 62.58M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -10 -11 -11 -12 -14 -15 -14 -13 -14 -16
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Design Therapeutics remains a clinical-stage biotechnology company with no reported revenue through the second quarter of 2026. The financial statements show a well-capitalized but consistently loss-making business: research spending is increasing, operating cash burn remains significant, and equity issuance has expanded the share count.

  • Strong liquidity position: As of June 30, 2026, Design Therapeutics held $12.9 million in cash and $194.5 million in short-term investments, or approximately $207.5 million in liquid assets.
  • Low leverage: Total liabilities were just $13.3 million compared with $201.9 million of common equity. The balance sheet contains no reported debt, which reduces near-term financial risk.
  • Investment income provides partial support: Interest and investment income contributed $2.0 million in the second quarter of 2026 and has helped offset a portion of operating expenses.
  • Limited capital spending needs: Capital expenditures were only $21,000 in the second quarter of 2026, indicating that cash use is primarily related to research and corporate operations rather than heavy infrastructure investment.
  • Investment portfolio activity is substantial: The company generated $15.1 million of net investing cash flow in Q2 2026, primarily because investment maturities and sales exceeded new purchases. This reflects treasury management rather than operating profitability.
  • Cash runway appears meaningful but depends on development spending: Q2 2026 operating cash burn was $15.5 million. Annualizing that quarterly burn suggests roughly $62 million of annual operating cash use, implying several years of liquidity based on current liquid assets, although clinical development costs could increase materially.
  • No revenue or gross profit: Revenue has remained at zero in every provided income statement period. Design Therapeutics therefore has no operating revenue to fund research, and future value depends heavily on clinical progress and potential financing or partnering activity.
  • Net losses are persistent and generally widening: The company reported a $20.2 million net loss in Q2 2026, compared with $17.6 million in Q1 2026 and $19.1 million in Q2 2025. Quarterly losses have increased from approximately $11.1 million in Q1 2024 and $13.7 million in Q4 2024.
  • Research spending continues to rise: Research and development expense reached $16.4 million in Q2 2026, up from $15.7 million in Q2 2025 and $9.8 million in Q1 2024. Total operating expenses increased to $22.2 million from $15.0 million over the same two-year comparison.
  • Operating cash burn is accelerating: Cash used in operating activities was $15.5 million in Q2 2026, up from $14.4 million in Q2 2025 and $9.5 million in Q3 2024. Continued negative operating cash flow could shorten the runway if spending rises or investment income declines.
  • Shareholder dilution is a continuing risk: Weighted-average basic shares increased to 62.5 million in Q2 2026 from 56.6 million in Q4 2024. Design Therapeutics raised approximately $19.9 million through common equity issuance in Q1 2026, suggesting that future financing could further dilute existing shareholders.

Overall, Design Therapeutics has a relatively strong balance sheet and several years of apparent liquidity at the current burn rate, but it remains entirely dependent on research progress rather than commercial revenue. Investors should focus on clinical milestones, the pace of R&D spending, future equity financing, and whether cash burn continues to increase.

10/13/26 07:22 AM ETAI Generated. May Contain Errors.

Design Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Design Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Design Therapeutics' net income appears to be on a downward trend, with a most recent value of -$69.79 million in 2025, falling from -$8.28 million in 2020. The previous period was -$49.59 million in 2024. See Design Therapeutics' forecast for analyst expectations on what's next for the company.

Design Therapeutics' total operating income in 2025 was -$79.47 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $79.47 million

Over the last 5 years, Design Therapeutics' total revenue changed from $226 thousand in 2020 to $0.00 in 2025, a change of -100.0%.

In the past 11 quarters, Design Therapeutics' cash and equivalents has ranged from $12.77 million in Q1 2026 to $45.70 million in Q2 2024, and is currently $12.91 million as of their latest financial filing in Q2 2026.

Design Therapeutics had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2020.

Over the last 5 years, Design Therapeutics' book value per share changed from -0.72 in 2020 to 3.73 in 2025.


Related Companies

Financial statements for NASDAQ:DSGN last updated on 8/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel